JP2022544771A5 - - Google Patents
Info
- Publication number
- JP2022544771A5 JP2022544771A5 JP2022508874A JP2022508874A JP2022544771A5 JP 2022544771 A5 JP2022544771 A5 JP 2022544771A5 JP 2022508874 A JP2022508874 A JP 2022508874A JP 2022508874 A JP2022508874 A JP 2022508874A JP 2022544771 A5 JP2022544771 A5 JP 2022544771A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion molecule
- ecd
- molecule according
- cytokine
- masking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885471P | 2019-08-12 | 2019-08-12 | |
| US62/885,471 | 2019-08-12 | ||
| US202063015644P | 2020-04-26 | 2020-04-26 | |
| US63/015,644 | 2020-04-26 | ||
| US202063019319P | 2020-05-02 | 2020-05-02 | |
| US63/019,319 | 2020-05-02 | ||
| US202063044294P | 2020-06-25 | 2020-06-25 | |
| US63/044,294 | 2020-06-25 | ||
| PCT/US2020/046000 WO2021030483A1 (en) | 2019-08-12 | 2020-08-12 | Il-2 fusion proteins that preferentially bind il-2ralpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544771A JP2022544771A (ja) | 2022-10-21 |
| JP2022544771A5 true JP2022544771A5 (https=) | 2023-07-21 |
| JP7690458B2 JP7690458B2 (ja) | 2025-06-10 |
Family
ID=72240507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022508874A Active JP7690458B2 (ja) | 2019-08-12 | 2020-08-12 | 優先的にｉｌ－２ｒアルファに結合するｉｌ－２融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220306714A1 (https=) |
| EP (1) | EP4013775A1 (https=) |
| JP (1) | JP7690458B2 (https=) |
| CN (1) | CN114222764B (https=) |
| AU (1) | AU2020329216A1 (https=) |
| CA (1) | CA3148505A1 (https=) |
| WO (1) | WO2021030483A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240141853A (ko) | 2017-08-03 | 2024-09-27 | 신톡스, 인크. | 자가면역 질환의 치료를 위한 사이토카인 접합체 |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| AU2019271148B9 (en) | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| SG11202102930YA (en) | 2018-11-08 | 2021-04-29 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
| EP3923974A4 (en) | 2019-02-06 | 2023-02-08 | Synthorx, Inc. | IL-2 CONJUGATES AND METHODS OF USE THEREOF |
| EP3969035A4 (en) | 2019-05-14 | 2023-06-21 | Werewolf Therapeutics, Inc. | SEPARATION UNITS AND METHODS AND THEIR USE |
| CA3141626A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| EP4017540A1 (en) | 2019-08-23 | 2022-06-29 | Synthorx, Inc. | Il-15 conjugates and uses thereof |
| US12234271B2 (en) | 2019-09-10 | 2025-02-25 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| MX2022005666A (es) | 2019-11-14 | 2022-10-07 | Werewolf Therapeutics Inc | Polipeptidos de citocina activables y metodos de uso de los mismos. |
| CA3165927A1 (en) | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| IL298136A (en) | 2020-05-13 | 2023-01-01 | Bonum Therapeutics Inc | Preparations of protein complexes and methods of using them |
| WO2022115865A2 (en) | 2020-11-25 | 2022-06-02 | Xilio Development, Inc. | Tumor-specific cleavable linkers |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| AU2022306974A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
| WO2024212151A1 (en) * | 2023-04-13 | 2024-10-17 | Adagene Pte. Ltd. | Masked antibodies, libraries and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| US9580486B2 (en) * | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| PT3172227T (pt) * | 2014-07-21 | 2019-12-06 | Delinia Inc | Moléculas que ativam seletivamente células t reguladoras para o tratamento de doenças autoimuneis |
| JP7178906B2 (ja) * | 2016-05-19 | 2022-11-28 | ザ ジェネラル ホスピタル コーポレイション | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| WO2019222296A1 (en) * | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| WO2020023702A1 (en) * | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| CA3165927A1 (en) * | 2020-01-11 | 2021-07-15 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
-
2020
- 2020-08-12 CA CA3148505A patent/CA3148505A1/en active Pending
- 2020-08-12 AU AU2020329216A patent/AU2020329216A1/en active Pending
- 2020-08-12 WO PCT/US2020/046000 patent/WO2021030483A1/en not_active Ceased
- 2020-08-12 CN CN202080057045.6A patent/CN114222764B/zh active Active
- 2020-08-12 JP JP2022508874A patent/JP7690458B2/ja active Active
- 2020-08-12 EP EP20761693.9A patent/EP4013775A1/en active Pending
- 2020-08-12 US US17/634,890 patent/US20220306714A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022544771A5 (https=) | ||
| CN109071654B (zh) | 靶向Fc受体样5的抗体及使用方法 | |
| US11566071B2 (en) | Nucleic acid molecules encoding anti-GPRC5D antibodies | |
| CN113166246B (zh) | 一种抗体及其用途 | |
| JP2021510710A5 (https=) | ||
| US20210388049A1 (en) | Novel Rationally Designed Protein Compositions | |
| CA2411374A1 (en) | Dual specificity antibodies and methods of making and using | |
| WO2019091436A1 (zh) | 4-1bb抗体及其制备方法和应用 | |
| JP2015519375A5 (https=) | ||
| CN112358548B (zh) | 人抗IFN-α抗体、IFN-α结合片段、多核苷酸、组合物、试剂盒及应用和制备方法 | |
| KR20250143753A (ko) | 다가 및 다중특이적 시토카인 길항제 | |
| JP2020508694A5 (https=) | ||
| CN117337306A (zh) | 靶向pd-l1和cd73的特异性结合蛋白 | |
| CN110878122B (zh) | 重组抗pd-l1单克隆抗体 | |
| JP6974500B2 (ja) | ＦｃＲｎに対するＩｇＧ様抗体の結合親和性を増加し、その血清半減期を延長させる方法 | |
| CN120554509A (zh) | 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用 | |
| EP4650368A1 (en) | Tetravalent agonists of erythropoietin receptor | |
| CN120548328A (zh) | 混杂的cd3结合分子 | |
| CN117986371A (zh) | 结合CD123和γ-δT细胞受体的抗体 | |
| JP2025541365A (ja) | 多価造血細胞係合因子または活性化因子 | |
| JP2024541576A (ja) | 新規特異的アンタゴニスト抗ＳＩＲＰｇ抗体 | |
| JP2024533485A5 (https=) | ||
| WO2026022767A1 (ko) | B7-h3을 표적하는 항체, 및 이를 포함하는 키메라 항원 수용체 | |
| CN117460746A (zh) | 靶向pd1和/或ox40的特异性结合蛋白 | |
| HK40002168A (en) | Antibodies targeting fc receptor-like 5 and methods of use |